QOLBET: Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With Betaferon in Korea.

Trial Profile

QOLBET: Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With Betaferon in Korea.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2012

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms QOLBET
  • Sponsors Bayer
  • Most Recent Events

    • 19 Apr 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Apr 2010 Planned initiation date changed from Jun 2010 to Jan 2011 as reported by ClinicalTrials.gov.
    • 25 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top